MIR641

Summary

MIR641 (microRNA 641, HGNC:32897) is a microRNA gene on chromosome 19q13.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693226 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32897
Approved symbol	MIR641
Name	microRNA 641
Location	19q13.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-641
Ensembl gene	ENSG00000207631
Ensembl biotype	miRNA
Entrez	693226
RNAcentral	URS000075CBEE — miRNA, 99 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384899

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384899 — 1 exons

Exon	Start	End
ENSE00001499906	40282543	40282641

Expression profiles

Bgee: expression breadth ubiquitous, 111 present calls, max score 95.59.

Top tissues by expression

111 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	95.59	gold quality
adrenal tissue	UBERON:0018303	94.65	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.94	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.62	gold quality
cerebellar hemisphere	UBERON:0002245	85.07	gold quality
right ovary	UBERON:0002118	84.77	gold quality
left ovary	UBERON:0002119	84.69	gold quality
skeletal muscle tissue	UBERON:0001134	84.22	gold quality
body of uterus	UBERON:0009853	84.10	gold quality
pituitary gland	UBERON:0000007	83.97	gold quality
ovary	UBERON:0000992	83.93	gold quality
myometrium	UBERON:0001296	83.18	gold quality
metanephros cortex	UBERON:0010533	82.57	gold quality
endometrium	UBERON:0001295	81.86	gold quality
right coronary artery	UBERON:0001625	81.86	gold quality
adenohypophysis	UBERON:0002196	81.71	gold quality
urinary bladder	UBERON:0001255	81.33	gold quality
endocervix	UBERON:0000458	81.18	gold quality
left uterine tube	UBERON:0001303	81.16	gold quality
fallopian tube	UBERON:0003889	80.97	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.66	gold quality
left lobe of thyroid gland	UBERON:0001120	80.40	gold quality
kidney	UBERON:0002113	80.06	gold quality
thyroid gland	UBERON:0002046	79.91	gold quality
muscle of leg	UBERON:0001383	79.65	gold quality
lower esophagus muscularis layer	UBERON:0035833	79.61	gold quality
stomach	UBERON:0000945	79.59	gold quality
brain	UBERON:0000955	79.53	gold quality
lower esophagus	UBERON:0013473	79.52	gold quality
prefrontal cortex	UBERON:0000451	79.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.39

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 13)

• Our findings suggest that increased expression of miR-641 significantly contributes to erlotinib resistance development in NSCLC cells through activating ERK signaling by targeting NF1 and that inhibition of miR-641 may reverse acquired resistance of NSCLC cells to erlotinib treatment. (PMID:29493886)
• CRNDE level was upregulated in NSCLC, and its knockdown suppressed NSCLC cells proliferation and enhanced apoptosis, whereas miR-641 antagonized the regulatory effect of CRNDE knockdown by directly binding to CRNDE. (PMID:30982057)
• These results demonstrated that overexpression of TUSC8 could inhibit the invasion and migration of cervical cancer cells by upregulating PTEN via miR-641. (PMID:31033083)
• Long non-coding RNA OIP5-AS1 promotes proliferation of gastric cancer cells by targeting miR-641. (PMID:31858545)
• Circular RNA CDR1as Exerts Oncogenic Properties Partially through Regulating MicroRNA 641 in Cholangiocarcinoma. (PMID:32423991)
• Long non-coding RNA LINC01963 inhibits progression of pancreatic carcinoma by targeting miR-641/TMEFF2. (PMID:32559621)
• Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and MDM2. (PMID:32667627)
• Circular RNA circSETD3 hampers cell growth, migration, and stem cell properties in bladder cancer through sponging miR-641 to upregulate PTEN. (PMID:34288821)
• miR-641 Inhibited Cell Proliferation and Induced Apoptosis by Targeting NUCKS1/PI3K/AKT Signaling Pathway in Breast Cancer. (PMID:35069784)
• LINC00665 sponges miR-641 to promote the progression of breast cancer by targeting the SNF2-related CREBBP activator protein (SRCAP). (PMID:35152838)
• MiR-641 Exacerbates the Progression of Ischemic Stroke Through the MCL-1/Wnt/beta-Catenin Pathway. (PMID:35975488)
• Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis. (PMID:38331968)
• The miR-641-STIM1 and SATB1 axes play important roles in the regulation of the Th17/Treg balance in ITP. (PMID:38755179)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.